A forum for researchers, students and applicants in the field of cyclodextrin technology
A disorder of cholesterol homeostasis is one of the main initiating factors in the progression of atherosclerosis (AS). Metabolism and
Despite advancements in contemporary therapies, cardiovascular disease from atherosclerosis remains a leading cause of mortality worldwide. Supported lipid bilayers (SLBs)
Tumor immunotherapy, compared with other treatment strategies, has the notable advantage of a long-term therapeutic effect for preventing metastasis and
Cyclodextrins (CDs), the therapeutic candidates for Niemann–Pick disease type C (NPC), function dually as a shuttle and sink that catalytically
Up to 12 fully funded PhD positions have been offered to highly motivated and talented researchers at the Cologne Graduate
Neuromuscular blocking agents (NMBAs) are commonly used in the practice of anesthesiology for skeletal muscle relaxation to facilitate tracheal intubation,
Niemann-Pick disease type C (NPC) is a rare, fatal, pan-ethnic, autosomal recessive lysosomal storage disease characterized by progressive major organ
With immense sadness we have to announce that an outstanding Scientist, Dr. David Begley passed away on Thursday 6th July
Non-alcoholic fatty liver disease and Cyclodextrins Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease with no
β-Cyclodextrin (β-CD) and derivatives are approved therapeutics in >30 clinical settings. β-CDs have also shown promise as therapeutics for treatment
